CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 96 enrolled
Drug / intervention
Doxazosin +1 moredrug
Likely dose
Doxazosin 4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01145183
NCT01145183Phase 2Completed
CompareCT.gov

H-26605: Pharmacogenetics of Doxazosin for Cocaine Dependence

Baylor College of Medicine·interventional·Posted Jun 16, 2010·Updated Jul 22, 2019

In Brief

A Phase 2 clinical trial evaluating Doxazosin and Placebo for Cocaine Dependence. Completed, enrolled 96 participants across 1 site.

Detailed Summary

Doxazosin, an alpha 1-adrenergic receptor antagonist, may play an important role in cocaine addiction in humans. This study will evaluate to what extent the prospective screening for catecholamine related polymorphisms for alpha 1 NE receptor/transporter, COMT and DBH as main targets predict the treatment efficacy of doxazosin for cocaine-using behavior.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCocaine Dependence
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 16, 2010
Enrollment StartMar 1, 2010
Primary CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 16.0 years ago

Interventions

Doxazosindrug

Doxazosin is initiated at 4 mg/wk, and titrated up to a maximum of 8 mg/day over approximately 2 weeks. Participants will be maintained on 6mg-8mg daily dosing until week 13. The subjects will undergo the discontinuation from the study medication during weeks 14 -15.

Placebodrug

Matched placebo daily dosing